The key idea
Most people know their cycle as a bleed that arrives on a rough schedule.
The hormones underneath it are a lot more informative than that.
Once you can read what they're doing, the information you've been collecting without a framework starts to make sense.
What Is Worth Knowing
The cycle has four phases, each with a distinct hormone signature.
The follicular phase starts on day one of your period: FSH rises, follicles develop, oestrogen climbs.
The ovulatory phase is typically around day 12–16, but highly variable.
It is triggered by a sharp LH surge 24–36 hours before the dominant follicle releases an egg.
The luteal phase follows: progesterone rises and the endometrium thickens.
Oestrogen has a secondary rise, then both hormones fall if fertilisation doesn't occur.
The lining sheds, and the cycle starts again.
All of this is orchestrated by the brain (the hypothalamic-pituitary axis).
That is why things like sleep disruption, stress, and low body weight can shift timing.
Physical signs track the hormonal phases closely if you know what you're looking at.
Cervical fluid changes from absent or sticky in the early follicular phase, to creamy.
Then it becomes egg-white quality (EWCM: clear, stretchy, slippery) at peak fertility, just before ovulation.
Basal body temperature (BBT) rises by 0.2–0.5°C after ovulation, due to progesterone.
This confirms ovulation has happened but does not predict it.
Breast tenderness in the luteal phase is a progesterone effect. It usually resolves before your period.
Spotting in the luteal phase, particularly before day 10 post-ovulation, can signal insufficient progesterone support.
It is worth flagging.
Cycle length variation is more informative than most people realise. A 'normal' cycle is 24–35 days.
Anything outside that consistently warrants investigation, not reassurance.
Cycles under 24 days often have a shortened follicular phase, meaning less time for follicle development.
Cycles over 35 days often mean delayed or absent ovulation.
Luteal phase length below 10 days may indicate inadequate progesterone.
A progesterone test on day 21 may not fall 7 days post-ovulation if your cycle is long.
That is a common reason for a falsely low day-21 result.
Cycle tracking apps use statistical averages and a fixed-luteal-phase assumption, usually 14 days.
They use these to back-calculate ovulation from your last period.
They don't measure your hormones: they guess from population norms.
For someone with irregular cycles, or a short or long luteal phase, the prediction can be significantly wrong.
Apps are a useful log and a poor predictor.
Combining a temperature chart with cervical fluid observation gives you actual data from your own body.
It takes two to three cycles to learn the pattern.
But it tells you considerably more than the app's fertile window.
Track the Things That Actually Tell You Something
Pick two to three signs and track consistently for three cycles before drawing conclusions.
Cervical fluid quality (dry / sticky / creamy / EWCM) noted daily.
BBT on waking, same time, before getting up: a thermometer to two decimal places matters here.
Bleed start and length, including any spotting.
Three cycles of consistent data is the minimum for a pattern to emerge.
One cycle is just a single data point.
If your cycles are irregular, BBT won't predict ovulation but will confirm it retrospectively, which is still useful.
What to Bring to a Consultation
Day 2–5 bloods (FSH, LH, oestradiol) assess the follicular phase baseline.
Day-21 progesterone assesses whether ovulation produced enough progesterone.
But 'day 21' is only meaningful if you ovulated around day 14.
If your cycle is 35 days and you ovulate around day 21, the blood needs to be drawn around day 28.
Bring your actual cycle length data to the appointment.
'I ovulate around day X based on three cycles of BBT tracking' is more useful than 'my cycle is irregular'.
Clinicians who are given real data can interpret it.
Clinicians who are given 'I think I'm about day 21' often can't.
An information resource, not a medical device and not SaMD.
CSO safety framework completed.
Clinical decisions rest with the treating clinician.